Prelude Therapeutics Incorporated
PRLD
$3.36
$0.061.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.50M | -111.77M | -124.32M | -127.83M | -127.17M |
| Total Depreciation and Amortization | 1.71M | 1.78M | 1.76M | 1.78M | 1.77M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.08M | 14.25M | 16.99M | 18.17M | 18.30M |
| Change in Net Operating Assets | 28.41M | -4.42M | -2.78M | 2.55M | 4.22M |
| Cash from Operations | -56.30M | -100.17M | -108.35M | -105.33M | -102.89M |
| Capital Expenditure | -67.00K | -120.00K | -183.00K | -522.00K | -764.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.53M | 136.04M | 106.74M | 121.68M | 90.96M |
| Cash from Investing | 53.46M | 135.92M | 106.56M | 121.16M | 90.19M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -208.00K | -359.00K | -507.00K | -550.00K | -395.00K |
| Issuance of Common Stock | 25.04M | 216.00K | 272.00K | 437.00K | 439.00K |
| Repurchase of Common Stock | -17.00K | -19.00K | -27.00K | -43.00K | -54.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | -26.00K | -110.00K | -110.00K |
| Cash from Financing | 24.82M | -162.00K | -288.00K | -266.00K | -120.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 21.97M | 35.59M | -2.08M | 15.56M | -12.82M |